FDA Grants RMAT Designation for VY-AADC for Parkinson’s Disease

(June 22, 2018) – Voyager Therapeutics announced that the US Food and Drug Administration granted regenerative medicine advanced therapy (RMAT) designation for VY-AADC gene therapy for treatment of Parkinson’s disease in patients with motor fluctuations refractory to medical management. Read more

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

This month is? (Anti-Spam)

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2018 The Parkinson Alliance. All rights reserved.